Breast Cancer Now

Recent papers from Breast Cancer Now

1. M-CSF–driven TAM remodelling and actomyosin reactivation underlie BRAFi resistance in melanomaJournal of Experimental & Clinical Cancer Research · 2026
2. Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapyBritish Journal of Cancer · 2026
3. Combined inhibition of DNA Polymerase Theta and ATR targets MYBL2-high triple-negative breast cancer stem cellsJournal of Clinical Investigation · 2026
4. Meiotic recombination proteins in cancerDNA repair · 2026
5. A genome-scale adaptation map identifies the FANCM-RMI1/2 complex as an opposing modulator of cell fitness upon BRCA1 or BRCA2 lossMolecular Cell · 2026
6. Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysisRadiotherapy and Oncology · 2026
7. PUM3 is an essential suppressor of replication stress in homologous recombination deficient breast cancerNature Communications · 2026
8. The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patientsFrontiers in Cell and Developmental Biology · 2026
9. Retrotransposable element derepression distinguishes DNMT3A-mutant from TET2-mutant clonal haematopoiesisGeroScience · 2026
10. Massively parallel functional profiling prioritizes breast cancer risk variants and implicates CCDC88C in ER-positive breast cancerHuman Genetics and Genomics Advances · 2026
11. Physical activity in advanced urological cancers undergoing immune checkpoint inhibitor treatment: a qualitative study exploring patient perspectives and experiencesSupportive Care in Cancer · 2026
12. 54 Access to Prehabilitation in UK Neuro-Oncology: Insights from a UK-wide review of adult brain tumour services (2024-2026)Neuro-Oncology · 2026
13. The anion channel GPR89 is a tumor-specific dependency in breast cancerNature Communications · 2026
14. Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast CancerJAMA Oncology · 2026
15. Genome-wide DNA methylation profiling of triple-negative breast cancer uncovers epigenetic biomarkers of tumor identity and the immune microenvironmentnpj Breast Cancer · 2026
16. Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanomaJournal of Experimental & Clinical Cancer Research · 2026
17. Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapyJournal for ImmunoTherapy of Cancer · 2026
18. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialAnnals of Oncology · 2026
19. Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation TestAllergy · 2026
20. Artificial intelligence in oncology: empowering clinicians for responsible integrationESMO Real World Data and Digital Oncology · 2026